Agios sinks as sickle cell drug misses pain crisis goal

Agios Pharmaceuticals

19/11/2025 12:23

** Shares of drugmaker Agios Pharmaceuticals AGIO.O fall 31% to $31.49 premarket

** Co says its experimental drug, mitapivat, failed to show clear benefit in reducing painful crises for people with sickle cell disease, despite meeting its main target of improving blood levels in late-stage trial

** AGIO says late-stage trial enrolled 207 patients; 41% on drug saw hemoglobin rise vs 3% on placebo

** Drug lowered bilirubin, marker of red blood cell breakdown; safety profile consistent with prior studies, AGIO says

** Co adds it plans to share full results with U.S. regulators and seek approval for mitapivat as treatment for sickle cell disease

** Up to last close, stock up ~38% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))